



Intravitreal implants for treatment of posterior segment diseases

Essay

**Submitted for partial fulfillment of M.Sc. degree in
Ophthalmology**

By

Zaid Ali Hassan Al-Sharafi

M.B. B.Ch.

**Faculty of medicine
Cairo university**

Under supervision of

Dr. Karim Adly Raafat

**Professor of ophthalmology
Faculty of medicine
Cairo university**

Dr. Mohammed Abdelmonaem Hassaballah

**Professor of ophthalmology
Faculty of medicine
Cairo university**

Dr. Nahla Borhan Abuhussein

**Associate professor of ophthalmology
Faculty of medicine
Cairo university**

**Faculty of medicine
Cairo university**

2012

Acknowledgement

I would like to express my deep and sincere gratitude to Pro. Dr. Karim Adly Raafat professor of ophthalmology, faculty of medicine, Cairo university. Also with immense gratitude that I acknowledge the support of Pro. Dr. Mohammed Abdelmonaem Hassaballah professor of ophthalmology, faculty of medicine, Cairo university. Also I would like to express my deep and sincere gratitude to assistant Pro. Dr. Nahla Borhan Abuhusseini, assistant professor of ophthalmology, faculty of medicine, Cairo university without their efforts, supervision, encouragement and guidance this work would not have been possible.

Abstract

Aln the ongoing armamentarium against sight threatening diseases not only the drug composition is a determining factor but also the way of delivery is a crucial point to consider. Novel methods of ophthalmic drug delivery are being developed to facilitate treatment of a variety of eye diseases.

In order to develop novel methods of ophthalmic drug delivery certain aspects should be considered.

The anatomy and the functional physiology of the eye plays an important role in ocular drug delivery and distribution.

The blood ocular barriers affect the extent of drug absorption and distribution intended to be delivered to the posterior segment of the eye.

Key Words :

Cerium oxide - Cytomegalo virus - Inner oBRB .

List of content

<i>list of abbereviation</i>	iv
<i>List of tables</i>	vi
<i>List of figures</i>	vii
<i>Introduction</i>	1
<i>Aim of the study</i>	2
<u>Chapter one</u> <u><i>Review of lecture</i></u>	
<i>Anatomical and physiological review.....</i>	3
<i>Barriers that restrict intraocular drug transport.....</i>	6
<u>Chapter two</u> <u><i>Methods of studying ocular pharmacokinetics</i></u>	
<i>Ocular pharmacokinetics using traditional methods ...</i>	14
<i>Ocular pharmacokinetics using MRI</i>	15
<i>Ocular pharmacokinetics using 3-D computer simulation "mathematical eye model"</i>	22

<u>Chapter three</u> <u>Intravitreal Implants; Types, Indications, Advantages and Disadvantages</u>	
<i>Potential sites for intraocular drug delivery device implantation</i>	25
<i>Various approaches employed for ophthalmic drug delivery to overcome the blood ocular barriers</i>	26
<i>Direct intravitreal injection</i>	26
<i>Intravitreal implantable device technology</i>	28
<i>Types of sustained release drug delivery devices</i>	29
<i>Specialized intravitreal implantable technologies for treatment of posterior segment eye diseases</i>	33
<i>Vitrasert</i>	33
<i>Retisert</i>	37
<i>Illuvien / Medidur</i>	42
<i>Posurdex</i>	46
<i>Scleral plug devices</i>	47
<i>Scleral discoid device</i>	49
<i>Novel helical device (I-Vation technology).....</i>	51
<i>Encapsulated cell technology</i>	53
.	

<u>Chapter four</u> <i>other drug delivery systems to posterior segment of the eye</i>	
<i>Particulate drug delivery systems</i>	55
<i>Nanoparticles and microparticles.....</i>	55
<i>Liposomes</i>	57
<i>Cortiject</i>	58
<i>Physical devices</i>	58
<i>Noninvasive iontophoretic ocular drug delivery device (visulex).....</i>	58
<i>Micro-electromechanical intraocular drug delivery Device</i>	60
<i>Ultrasound mediated microbubble drug delivery</i>	62
<i>Microcanulation of the suprachoroidal space</i>	63
<i>Summary</i>	66
<i>References.....</i>	69
<i>Arabic summary</i>	

List of abbreviations

<i>AMD</i>	<i>Age-related macular degeneration</i>
<i>ARPE-19</i>	<i>Activated retinal pigment epithelium</i>
<i>BCVA</i>	<i>Best corrected visual acuity</i>
<i>BM</i>	<i>Bruch's membrane</i>
<i>BRB</i>	<i>Blood retinal barrier</i>
<i>BRVO</i>	<i>Branch retinal vein occlusion</i>
<i>(CeO₂)</i>	<i>Cerium oxide</i>
<i>CME</i>	<i>Cystoid macular edema</i>
<i>CMT</i>	<i>central macular thickness</i>
<i>CMV</i>	<i>Cytomegalo virus</i>
<i>CNTF</i>	<i>Ciliary neurotrophic factor</i>
<i>CRVO</i>	<i>Central retinal vein occlusion</i>
<i>3D</i>	<i>3 dimensional</i>
<i>DDS</i>	<i>Drug delivery system</i>
<i>DME</i>	<i>Diabetic macular edema</i>
<i>DMSB</i>	<i>Dexamethasone sodium m-sulfobenzoate</i>
<i>DNA</i>	<i>Double stranded nucleic acid</i>
<i>DSMT</i>	<i>donut-shaped minitablet</i>
<i>EBV</i>	<i>Epstein barr virus</i>
<i>ECT</i>	<i>Encapsulated cell technology</i>
<i>EVA</i>	<i>Ethylene vinyl acetate</i>
<i>FAME</i>	<i>Flucinolone acetone in diabetic macular edema</i>
<i>FDA</i>	<i>Food and drug administration</i>
<i>Fig</i>	<i>Figure</i>

<i>Gd-DTPA</i>	<i>Gadolinium diethylene triamino pentaacetic acid</i>
<i>kda</i>	<i>atomic mass unit</i>
<i>iBRB</i>	<i>Inner oBRB</i>
<i>ILM</i>	<i>internal limiting membrane</i>
<i>IOP</i>	<i>Intraocular pressure</i>
<i>MEMS</i>	<i>microelectromechanical systems</i>
<i>MRI</i>	<i>Magnetic resonance imaging</i>
<i>NY</i>	<i>New York</i>
<i>oBRB</i>	<i>Outer oBRB</i>
<i>PGA</i>	<i>Polyglycolic acid</i>
<i>PLA</i>	<i>Polylactic acid</i>
<i>PLGA</i>	<i>Polylactic co-glycolic acid</i>
<i>PMM 2.1.2</i>	<i>Polymethylidene malonate</i>
<i>PVA</i>	<i>Polyvinyl alcohol</i>
<i>REETAC</i>	<i>Intravitreal bioerudivel controlled-release triamcinolone microsphere system</i>
<i>RPE</i>	<i>Retinal pigment epithelium</i>
<i>SVH</i>	<i>simulated vitreous humor</i>
<i>TA</i>	<i>Triamcinolone</i>
<i>USA</i>	<i>United States of America</i>
<i>VA</i>	<i>Visual acuity</i>
<i>VEGF</i>	<i>Vascular endothelial growth factor</i>
<i>VZV</i>	<i>Varicella zoster virus</i>

List of tables

Table No.	Description	Page
1	MRI methods for studying ocular drug delivery	15
2	Differences, advantages, and disadvantages of non-invasive ocular drug-delivery studies with MRI and the traditional ocular pharmacokinetic studies with the technique of dissection	21

List of figures

Fig. No	Description	Page
1	Schematic of the eye-ball structure.	3
2	Example of intravitreal drug delivery systems for vitreoretinal diseases. Disorders	5
3	Schematic of corneal structure and its cellular organization of various transport-limiting barriers	7
4	Shematic representations of subconjunctival or episcleral blood vessels, and lymphatics network	8
5	Schematic of blood-retinal barrier, and capillary wall in the retina and the choroid	10
6	In vitro release of Gd-DTPA from episcleral and intravitreal implants	16
7	MRI scan (coronal images) with an intravitreal implant inserted through the equator of the right eye	18
8	(a):Magnified views of the region of the posterior vitreous, retina, choroid, and sclera a histologic section of a normal rabbit eye	19
9	Concentration distribution of Gd-DTPA from the lens to the retina in in vivo MRI experiment	20
10	Concentration distribution of Gd-DTPA along a vertical line from the middle of the vitreous to the other side of the vitreous in in-vivo MRI experimental data	20
11	Geometry of mathematical eye model	22
12	Mathematical eye model study results	23

13	Potential sites for ocular drug delivery device administration	25
14	Vitrasert implant	34
15	retisert implant	38
16	Schematic implantation of retisert implant	41
17	Medidur implant	43
18	(a) the scleral plug drug delivery device (b) illustration of the device implanted through the scleral in the human eye (c) non-eroding reservoir device allowing for re-injection of depleted bioactive	48
19	Intrascleral discs	50
20	I-vation technology	51
21	A: I-vation site of implantation B: Cap of I-vation covered by conjunctiva (patient 7 days post implantation)	52
22	Encapsulated Cell Technology	54
23	Scheme of nanoparticles and microparticles	57

24	Visulex (a) A unique dose controller and drug applicator (b)The applicator selectively transports drug ions into the vitreous	59
25	microelectromechanical systems (MEMS) drug delivery device: (a) A cross-section of the micro-electrochemical drug delivery device depicting electrochemical pumping of drug into the eye (b) illustration of the implanted device under the conjunctiva in the anterior chamber of the human eye	61
26	Diagram showing Structure of a microbubble	62
27	Fiberoptic system for microcanulation of suprachoroidal space	65

Introduction

The unique anatomy and physiology of the eye renders it difficult to achieve an effective drug concentration at the target site. Therefore, efficient delivery of a drug past the protective ocular barriers accompanied with minimization of its systemic side effects remains a major challenge **(Rupenthal and Alany, 2007)**.

Diseases affecting the posterior segment of the eye are difficult to treat and take longer to combat by employing conventional topical or systemic drug delivery **(Maurice, 2001)**.

Research has been directed at specialized drug delivery technologies to the tissues of the posterior segment of the eye **(Visor, 1994)**.

Pharmacokinetics describes the quantitative relationship between administered dose and tissue concentration over time, it is an important tool in drug development. To optimize drug concentration at the target sites, pharmacokinetic studies are useful **(Kim et al, 2004)**.

Conventional techniques as fluorescein, MRI and 3D simulation eye models are methods of assessing ocular drug distribution **(Li et al , 2008)**.

A variety of approaches for drug delivery to the posterior segment of the eye have been explored over the last few decades. These approaches include direct intravitreal injections, drug loaded microparticle carriers as microspheres, nanospheres, and liposomes, transscleral drug delivery devices, and intravitreal devices using polymers **(Davis et al, 2004)**.

The pharmaceutical world is becoming more and more aware of intraocular drug delivery challenges, and revolutionary therapeutic advances are being invented and implemented which may have the potential to vastly improve patient care and quality of life. Among these most promising developments are intravitreal drug delivery devices designed to deliver drugs with precision directly to the vitreous, retina, and choroid **(Ashton et al, 2000)**.

An intraocular device can be designed as either bioerodable or non-bioerodable **(Choonara et al, 2010)**.

With the continued development of more potent drugs combined with research into novel delivery methods, there is a realistic hope that optimal therapeutic drug delivery for diseases of the posterior segment will be available in the near future **(Shalin et al, 2010)**.

Aim of the study:

To spotlights on the types, indications and complications of the intravitreal implants in the posterior segment of the eye and their future trends.

Anatomical and physiological review

The eye-ball is an organ protected from exogenous substances and external stress by various barriers (**Figure 1**), therefore, therapeutic drugs must be transported across several protective barriers regardless of which administration route is utilized, such as eye-drops, subconjunctival, sub-tenon's, intravitreal injection and/or implant. For the treatment of the anterior segment of the eye (cornea, conjunctiva, sclera and anterior uvea), usually topical ocular eye-drops are used. An eye-drop, irrespective of the instilled volume, often eliminates rapidly within five to six minutes after administration, and only a small amount (1–3%) of an eye-drop actually reaches the intraocular tissue (**Maurice and Mishima, 1984**).




Fig. (1). Schematic of the eye-ball structure. (Kuno and Fuji , 2011).